- Home
- TSHA vs NATH Comparison
TSHA vs NATH Comparison
Compare TSHA & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- NATH
- Stock Information
- Founded
- TSHA 2019
- NATH 1916
- Country
- TSHA United States
- NATH United States
- Employees
- TSHA N/A
- NATH N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- NATH Restaurants
- Sector
- TSHA Health Care
- NATH Consumer Discretionary
- Exchange
- TSHA Nasdaq
- NATH Nasdaq
- Market Cap
- TSHA 313.6M
- NATH 323.4M
- IPO Year
- TSHA 2020
- NATH N/A
- Fundamental
- Price
- TSHA $1.53
- NATH $77.67
- Analyst Decision
- TSHA Strong Buy
- NATH
- Analyst Count
- TSHA 8
- NATH 0
- Target Price
- TSHA $6.63
- NATH N/A
- AVG Volume (30 Days)
- TSHA 2.3M
- NATH 9.3K
- Earning Date
- TSHA 11-13-2024
- NATH 01-30-2025
- Dividend Yield
- TSHA N/A
- NATH 2.56%
- EPS Growth
- TSHA N/A
- NATH 11.31
- EPS
- TSHA N/A
- NATH 5.34
- Revenue
- TSHA $9,915,000.00
- NATH $143,757,000.00
- Revenue This Year
- TSHA N/A
- NATH N/A
- Revenue Next Year
- TSHA N/A
- NATH N/A
- P/E Ratio
- TSHA N/A
- NATH $14.62
- Revenue Growth
- TSHA N/A
- NATH 7.04
- 52 Week Low
- TSHA $1.19
- NATH $63.01
- 52 Week High
- TSHA $4.32
- NATH $94.97
- Technical
- Relative Strength Index (RSI)
- TSHA 34.16
- NATH 40.79
- Support Level
- TSHA $1.56
- NATH $75.15
- Resistance Level
- TSHA $1.75
- NATH $78.47
- Average True Range (ATR)
- TSHA 0.16
- NATH 1.50
- MACD
- TSHA -0.02
- NATH 0.12
- Stochastic Oscillator
- TSHA 3.57
- NATH 48.00
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.